Tirzepatide Dose: What the Schedule Looks Like and Why It's Built This Way

The decision at the start: why 2.5 mg is where everyone begins

When someone is prescribed tirzepatide, the 2.5 mg dose comes first for every patient. That might feel low, and it is, deliberately. The first pen's job is to let your body adjust to slowed gastric emptying and the changes in appetite signalling that the medicine produces. Pushing straight to a higher dose would mean a sharp increase in nausea and digestive side effects for most people, which often leads to stopping treatment early. Starting gradually gives the GI system time to settle.

This is why the 2.5 mg tirzepatide pen is described in the SmPC as a tolerability dose rather than a therapeutic one. Most people notice modest appetite changes at this stage, but significant weight loss tends to come later as the dose rises. The NHS tirzepatide medicines page sets this out clearly, the schedule is designed to build tolerance, not to treat immediately at full strength.

In practice, many people find the 2.5 mg period easier than they expected. Others still experience some nausea in the first week or two. Either is normal. The prescriber's role at this stage is to confirm you're tolerating it before recommending the next step.

Steps two through six: what drives each dose increase

After four weeks at 2.5 mg, the standard step is up to 5 mg, a move that our tirzepatide 5 mg page covers in detail, including what most people notice during that transition. From there the schedule continues: 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg, each typically separated by a minimum of four weeks. The word 'minimum' matters here. There is no rule requiring a step up at exactly four weeks; the step happens when it is clinically appropriate.

The decision to increase is shaped by two things. First, tolerability, if side effects are still troublesome, staying at the current dose longer is usually the right call. Second, response, if weight loss has plateaued at a given dose and the current dose is well tolerated, increasing may produce further benefit. This is a clinical conversation, not a tick-box exercise. Dose increases at nume require evidence of your current weight and a prescriber review; the same process applies whether you're moving from 5 mg to 7.5 mg or considering whether 15 mg is genuinely the right end-point for you. Learn more about how the full range is structured on the tirzepatide doses overview.

Not everyone reaches 15 mg, and not everyone needs to. NICE guidance (TA1026) notes that if weight loss is less than 5% after six months at the highest tolerated dose, continuing should be reviewed with the prescriber. That is a useful benchmark, not a reason to panic, it exists to make sure treatment is genuinely working for you.

What the trial data shows at different tirzepatide doses

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed 2,539 adults with obesity over 72 weeks. Average weight reduction at the 10 mg dose was around 19.5%, and at 15 mg around 20–21%, figures that are meaningfully higher than those seen with GLP-1-only medicines in comparable trials. A later head-to-head (SURMOUNT-5) confirmed that tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over the same period.

What the data cannot do is predict any individual's response. Genetics, baseline weight, diet, activity and how well GI side effects are managed all influence outcomes. That is precisely why the schedule is titrated rather than fixed. The Mounjaro treatment guide has a fuller breakdown of the evidence behind tirzepatide for weight management.

One practical note: if you're comparing treatment options and want to understand the cost picture at different doses, our weight-loss treatments page sets out what the private prescription process involves, useful context before a consultation.

What can affect which dose is right for you

The licensed eligibility criteria set a floor: adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition. But eligibility only opens the door. The dose that is right for a specific person depends on how they respond at each step, including at the 1 mg tirzepatide stage that some titration schedules incorporate, what other medicines they take, and any relevant health history.

Tirzepatide can reduce the absorption of oral medicines, including the contraceptive pill, during the first four weeks of treatment and for four weeks after each dose increase. Women taking oral contraceptives are advised to use an additional non-oral method during those windows. That is a detail worth raising at consultation rather than managing alone. Our clinical team at nume includes GPhC-registered Independent Prescribers who review every case personally, the same day you submit, typically before the afternoon is out.

Storage matters too, and is dose-independent: all tirzepatide pens should be kept refrigerated at 2–8°C. The exact room-temperature window is detailed in the Patient Information Leaflet that comes with each pen; the nume FAQs also cover common storage questions.

If you are weighing up whether to start, or wondering which dose makes sense given your history, a free clinical consultation is the right next step. A prescriber can work through your situation in full, which is exactly what the weight-loss treatments consultation is designed for.